Point72 Asset Management L.P. grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 229.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,329,200 shares of the biopharmaceutical company’s stock after buying an additional 1,621,900 shares during the period. Point72 Asset Management L.P. owned 1.23% of Amicus Therapeutics worth $28,160,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the company. Strs Ohio grew its stake in shares of Amicus Therapeutics by 32.2% in the 2nd quarter. Strs Ohio now owns 16,000 shares of the biopharmaceutical company’s stock valued at $249,000 after buying an additional 3,900 shares during the period. Great West Life Assurance Co. Can boosted its position in shares of Amicus Therapeutics by 33.5% during the 2nd quarter. Great West Life Assurance Co. Can now owns 20,494 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 5,148 shares during the period. Swiss National Bank boosted its position in shares of Amicus Therapeutics by 1.8% during the 3rd quarter. Swiss National Bank now owns 328,700 shares of the biopharmaceutical company’s stock worth $3,974,000 after purchasing an additional 5,800 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Amicus Therapeutics by 15.5% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 47,745 shares of the biopharmaceutical company’s stock worth $746,000 after purchasing an additional 6,420 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Amicus Therapeutics by 0.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,046,768 shares of the biopharmaceutical company’s stock worth $31,970,000 after purchasing an additional 6,931 shares during the period.
FOLD has been the subject of a number of research analyst reports. BidaskClub cut shares of Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 18th. Cowen reaffirmed a “buy” rating and set a $31.00 price objective on shares of Amicus Therapeutics in a research report on Friday, October 12th. Zacks Investment Research cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Chardan Capital reaffirmed a “hold” rating and set a $15.00 price objective on shares of Amicus Therapeutics in a research report on Friday, October 12th. Finally, Citigroup initiated coverage on shares of Amicus Therapeutics in a research report on Monday, October 29th. They set a “neutral” rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.50.
NASDAQ:FOLD opened at $10.51 on Friday. The company has a quick ratio of 9.03, a current ratio of 9.12 and a debt-to-equity ratio of 0.78. Amicus Therapeutics, Inc. has a fifty-two week low of $9.65 and a fifty-two week high of $17.62.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.04). The company had revenue of $20.60 million for the quarter, compared to analysts’ expectations of $23.56 million. Amicus Therapeutics had a negative return on equity of 52.03% and a negative net margin of 463.82%. The business’s revenue for the quarter was up 89.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.41) EPS. On average, sell-side analysts expect that Amicus Therapeutics, Inc. will post -1.22 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Point72 Asset Management L.P. Has $28.16 Million Stake in Amicus Therapeutics, Inc. (FOLD)” was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.wkrb13.com/2018/12/16/point72-asset-management-l-p-has-28-16-million-stake-in-amicus-therapeutics-inc-fold.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Read More: How prevalent are 12b-1 fees?
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.